Skip to main content
Clinical Trials/NCT07205341
NCT07205341RecruitingNot Applicable

A Pilot Clinical Study to Assess Correlation Between Arterial Blood Volume Status and Cardiac Efficiency, and HemoCept Device Data in Trans-Aortic Valve Replacement (TAVR} Surgery

HemoCept Inc.1 site in 1 country20 target enrollmentStarted: April 29, 2025Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Recruiting
Sponsor
Enrollment
20
Locations
1
Primary Endpoint
Correlation of HemoCept device measurements with aortic valve pressure gradient changes.

Study Overview

Brief Summary

The objective of this Pilot Study is to demonstrate the efficacy of the Hemocept device in detecting changes in arterial blood volume and cardiac efficiency.

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Prospective

Eligibility Criteria

Ages
18 Years to 80 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Subjects or representatives must have voluntarily signed the informed consent form before any study related procedures.
  • •Subjects can be any gender but must be between (and including) the ages of 18 and
  • •Subject ls being treated by the participating healthcare facility .
  • •., Subject requires a trans-aortic valve replacement.
  • •Subject is able and willing to provide informed consent and HIPM authorization.
  • •Subject is able and willing to meet all study requirements.

Exclusion Criteria

  • •Subject is pregnant, breast-feeding, or intends to become pregnant during the course of the study.
  • •Subject has a personal medical history that includes:
  • •Long O-T syndrome
  • •Cardiac channelopathies

Outcomes

Primary Outcomes

Correlation of HemoCept device measurements with aortic valve pressure gradient changes.

Time Frame: Perioperative; immediately before procedure, and up to 24 hours after the procedure

The primary endpoint is the ability of the HemoCept device to properly detect changes consistent with aortic valve pressure gradient values, measured by echocardiogram pre and post TAVR procedure.

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor
HemoCept Inc.
Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials